Alivus Life Sciences Ltd Announces Q3 and Nine Months Financial Results for 2025

Alivus Life Sciences Ltd, formerly known as Glenmark Life Sciences Ltd, announced its unaudited financial results for the third quarter and nine months ended December 31, 2025. The company's revenue from operations stands at 6,868.17 million, with a total income of 6,523.00 million. The total expenses amounted to 2,876.16 million, resulting in a profit before tax of 19,003.48 million. The earnings per equity share (Face Value of = 2/- each) are (a) Basic (in 2) and (b) Diluted (in =). The company's paid-up equity share capital is 13,391.81 million, with other equity excluding revaluation reserve.